NC
MRTX

NinePointTwo Capital’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

NinePointTwo Capital’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-6,652
Closed -$240K – 338
2023
Q2 		$240K Buy
+6,652
New +$274K 0.09% 150
2022
Q3 		– Sell
-6,860
Closed -$460K – 233
2022
Q2 		$460K Buy
+6,860
New +$436K 0.16% 36

Other funds holding MRTX

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

NinePointTwo Capital's MRTX Position: Q3 2023 in Review

NinePointTwo Capital sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q3 2023, closing a stake of 6,652 shares — an estimated $240K sold.

NinePointTwo Capital first reported a position in MRTX in Q2 2022 and held it in 2 quarters. The position peaked at $460K in Q2 2022. 213 funds tracked by Wall St. Rank hold MRTX as of Q3 2023.

  • NinePointTwo Capital reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • NinePointTwo Capital sold 6,652 Mirati Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $240K.
  • NinePointTwo Capital first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2022 and held it in 2 quarters.
  • NinePointTwo Capital's Mirati Therapeutics, Inc. Common Stock position peaked at $460K in Q2 2022.
  • 213 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q3 2023.

Based on NinePointTwo Capital's 13F filing for Q3 2023, filed 14 Nov 2023.